07:39 AM EDT, 09/18/2024 (MT Newswires) -- Revive Therapeutics ( RVVTF ) , a specialty life sciences company, on Wednesday said it has decided not to pursue the development of a long-COVID diagnostic product. It will however, continue to explore the use of bucillamine as a potential treatment for the condition. The proposed Phase 2 study protocol is expected to be submitted by the end of this year and the clinical study is expected to be approved by the FDA in the first quarter of next year.

Revive also announced its strategic focus on advancing the clinical development of bucillamine in the areas of nerve agent exposure and emerging infections.

Bucillamine has been prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years.